Why IMU is a multi multi bagger, page-23606

Hi @Butterfrog, despite the fact that in previous MAST trial announcements the company has stated that "the trial commenced in May 2022 and is anticipated to run for approximately 24 months", this does not align to the clinical trial information where the estimated trial completion date has always been recorded as 31st January 2025. So in my view, there will be no update on the Mast trial presented tomorrow.

There appears to some confusion as to what information will be disclosed tomorrow.
As @GinoE correctly reported, the details of Abstract TPS2687 titled -

Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors

to be presented at the ASCO (American Society of Oncology) 2024 Annual General Meeting in Chicago will be released tomorrow at 8AM Aust EST.

https://meetings.asco.org/abstracts-presentations/238317

The poster will be presented by Dr Daneng Li from City of Hope Comprehensive Cancer Centre on June 2.

The closing date for abstract submission was 6th February 2024, 5 weeks prior to the commencement of the combination trial with Amgen;s Blincyto.
However, I am expecting we will see results of CD19 expression on the surface of infected tumor cells from the monotherapy run in cohorts. If this is confirmed, then we only need await the final phase being the kill shot from the combination cohorts with CAR-T bispecific Blincyto,.

I believe these results could be presented at SITC 2924 in Houston Texas November 6.
And if the results of pre-clinical trials are confirmed then we may well hear the thunder from the esteemed Professor Yuman Fong.

GLTAH - Go team Imugene
.